Roche is looking to offload its idiopathic pulmonary fibrosis drug Esbriet as more patients with the fatal lung disease opt for generic versions and Big Pharmas continue to shed non-core assets.
“As part of the normal process to review our portfolio of established products, we are currently evaluating potential options for Esbriet. This process will take several months until a final decision is taken,” a Roche spokesperson confirmed to Endpoints News via an emailed statement on Tuesday morning.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.